Oct, 2023

U.S.A.
News / Corporate
Astellas, BioLabs and Mitsui Fudosan Announce a Collaboration to Enhance the Life Science Ecosystems in Tsukuba and Kashiwa-no-ha, Japan
- Open Innovation Hub Named SakuLabTM-Tsukuba will open at the Astellas Tsukuba Research Center - TOKYO and BOSTON, Oct. 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and...
Read More

Sep, 2023

U.S.A.
News / Corporate
Two-time Emmy® Award-Winning Actor, Eric Stonestreet, Partners with Iveric Bio to Raise Awareness of Geographic Atrophy (GA)
GA is a form of age-related macular degeneration (AMD) that causes irreversible vision loss, affecting approximately 1.5 million people in the United States1,2 Eric and his mother, Jamey, are...
Read More
U.S.A.
News / Corporate
Astellas to Invest more than €330 Million in a New State-of-the-Art Facility in Tralee, Co. Kerry. Ireland
- Investment will build capabilities to supply the Astellas global market and accelerate the development and commercialisation of innovative medicines - TOKYO, Sept. 14, 2023 /PRNewswire/ --...
Read More

Aug, 2023

U.S.A.
News / Corporate
U.S. FDA Accepts Astellas' sNDA for CRESEMBA® (isavuconazonium sulfate) in Children
If approved, CRESEMBA will offer a new treatment option for pediatric patients facing certain invasive fungal infections NORTHBROOK, Ill., Aug. 10, 2023 /PRNewswire/ -- Astellas Pharma US, Inc....
Read More
U.S.A.
News / Corporate
Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy
IZERVAY is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials IZERVAY...
Read More